[
  {
    "pmid": "38450850",
    "citation": "{'name': 'Patnaik MM', 'authtype': 'Author', 'clusterid': ''} et al. Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management.. American journal of hematology (2024 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/38450850/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 31.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 23.1,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "a recent phase-3 study (DACOTA) comparing hydroxyurea and decitabine, in high-risk MP-CMML, showed similar overall survival at 23.1 versus 18.4 months, respectively, despite response rates being higher for decitabine (56% vs. 31%)"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The DACOTA study comparing hydroxyurea and decitabine in high-risk MP-CMML showed an overall survival of 23.1 months for hydroxyurea and a response rate of 31%.  No other response rates or survival data were available for hydroxyurea.",
    "has_efficacy_data": true
  },
  {
    "pmid": "36455187",
    "citation": "{'name': 'Itzykson R', 'authtype': 'Author', 'clusterid': ''} et al. Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023 Apr 1)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/36455187/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 35.0,
    "progression_free_survival_median": 10.3,
    "overall_survival_median": 21.9,
    "total_patients": 170,
    "cmml_patients": null,
    "supporting_quotes": [
      "One-hundred seventy patients received DAC (n = 84) or HY (n = 86).",
      "With a median follow-up of 17.5 months, median EFS was 12.1 months in the DAC arm and 10.3 months in the HY arm (hazard ratio [HR], 0.83; 95% CI, 0.59 to 1.16; P = .27).",
      "Compared with HY, DAC significantly reduced the risk of CMML progression or transformation to acute myelomonocytic leukemia (cause-specific HR, 0.62; 95% CI, 0.41 to 0.94; P = .005) at the expense of death without progression or transformation (cause-specific HR, 1.55; 95% CI, 0.82 to 2.9; P = .04).",
      "Median overall survival was 18.4 months in the DAC arm and 21.9 months in the HY arm (P = .67).",
      "Compared with HY, DAC significantly reduced the risk of CMML progression or transformation to acute myelomonocytic leukemia (cause-specific HR, 0.62; 95% CI, 0.41 to 0.94; P = .005) at the expense of death without progression or transformation (cause-specific HR, 1.55; 95% CI, 0.82 to 2.9; P = .04).",
      "Thirty (35%) HY patients (P = .0004)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "In this study comparing decitabine and hydroxyurea for advanced CMML, hydroxyurea demonstrated an overall response rate of 35%, a median overall survival of 21.9 months, and a median event-free survival of 10.3 months.  The study notes that decitabine showed a superior response rate, but overall survival was not significantly different.",
    "has_efficacy_data": true
  },
  {
    "pmid": "38106568",
    "citation": "{'name': 'Lafargue MC', 'authtype': 'Author', 'clusterid': ''} et al. Chronic Myelomonocytic Leukemia Patients With Lysozyme Nephropathy and Renal Infiltration Display Markers of Severe Disease.. Kidney international reports (2023 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/38106568/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 16,
    "cmml_patients": 116,
    "supporting_quotes": [
      "Sixteen patients (males, n = 14; median age 76.5 years [71.9-83] developed a kidney disease 6 months [1.6-25.6] after the diagnosis of CMML.",
      "Compared with 116 CMML controls, patients who had a kidney involvement had a higher monocyte count (P < 0.001), had more CMML-1 (P = 0.005), were more susceptible to develop an AML (P = 0.02), and were more eligible to receive a specific hematologic treatment, with hydroxyurea, or hypomethylating agents (P < 0.001), but no survival difference was seen between the 2 groups (P = 0.6978)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The study mentions that patients with kidney involvement were more likely to receive hydroxyurea treatment, but no specific response rates or survival data for hydroxyurea in CMML are provided.  No survival difference was seen between the kidney involvement group and the control group.",
    "has_efficacy_data": false
  },
  {
    "pmid": "39437109",
    "citation": "{'name': 'Sureda A', 'authtype': 'Editor', 'clusterid': ''} et al. Myelodysplastic/Myeloproliferative Neoplasms..  (2024)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/39437109/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "In case of rising leukocytosis and/or organ infiltration, hydroxyurea is the drug of choice."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 50,
    "efficacy_summary": "The abstract mentions hydroxyurea as the drug of choice for rising leukocytosis and/or organ infiltration in MDS/MPN patients, but provides no quantitative data on its efficacy in treating CMML.",
    "has_efficacy_data": false
  },
  {
    "pmid": "12057067",
    "citation": "{'name': 'Bennett JM', 'authtype': 'Author', 'clusterid': ''} et al. Chronic myelomonocytic leukemia.. Current treatment options in oncology (2002 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/12057067/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 24.0,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "The median age of patients with CMML is 70 years; the median survival is approximately 2 years."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The abstract mentions a median survival of approximately 2 years for CMML patients.  No other efficacy data such as response rates or PFS are provided for Hydroxyurea specifically.",
    "has_efficacy_data": true
  },
  {
    "pmid": "26848006",
    "citation": "{'name': 'Patnaik MM', 'authtype': 'Author', 'clusterid': ''} et al. Chronic Myelomonocytic Leukemia: Focus on Clinical Practice.. Mayo Clinic proceedings (2016 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/26848006/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "Hydroxurea and other cytoreductive agents have been used to control MPN-like features"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 50,
    "efficacy_summary": "The abstract mentions Hydroxyurea's use in controlling MPN-like features in CMML, but provides no quantitative efficacy data such as response rates or survival times.",
    "has_efficacy_data": false
  },
  {
    "pmid": "37300657",
    "citation": "{'name': 'Rezazadeh A', 'authtype': 'Author', 'clusterid': ''} et al. Proposals for Clinical Trials in Chronic Myelomonocytic Leukemia.. Current treatment options in oncology (2023 Aug)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/37300657/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "Hypomethylating agents are the mainstay of therapy but induce complete remissions in less than 20% of patients and do not prolong survival compared to hydroxyurea."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The abstract states that hypomethylating agents, not hydroxyurea, induce complete remissions in less than 20% of patients and do not improve survival.  No specific efficacy data for hydroxyurea in CMML is provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "28983777",
    "citation": "{'name': 'Moyo TK', 'authtype': 'Author', 'clusterid': ''} et al. Therapy for Chronic Myelomonocytic Leukemia in a New Era.. Current hematologic malignancy reports (2017 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/28983777/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The provided abstract does not contain any specific clinical efficacy data for hydroxyurea treatment in CMML patients.  The text mentions hydroxyurea as a conventional treatment but provides no quantitative results regarding its effectiveness.",
    "has_efficacy_data": false
  },
  {
    "pmid": "36845813",
    "citation": "{'name': 'Gurung S', 'authtype': 'Author', 'clusterid': ''} et al. Chronic myelomonocytic leukemia in a 72-year-old male from Nepal: A case report.. Annals of medicine and surgery (2012) (2023 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/36845813/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "Herein, the authors report a case of CMML in a 72-year-old male"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The case report describes a single CMML patient. No efficacy data for hydroxyurea is provided; the treatment plan is for azacitidine.",
    "has_efficacy_data": false
  },
  {
    "pmid": "24507815",
    "citation": "{'name': 'Itzykson R', 'authtype': 'Author', 'clusterid': ''} et al. Chronic myelomonocytic leukemia: myelodysplastic or myeloproliferative?. Best practice & research. Clinical haematology (2013 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/24507815/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 36.0,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "Median survival is 3 years"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The abstract mentions a median survival of 3 years (36 months) for CMML patients. No other efficacy data, such as response rates or PFS, is provided for Hydroxyurea treatment specifically.",
    "has_efficacy_data": true
  },
  {
    "pmid": "34123950",
    "citation": "{'name': 'Alromaih L', 'authtype': 'Author', 'clusterid': ''} et al. Chronic Neutrophilic Leukemia with Monocytosis.. European journal of case reports in internal medicine (2021)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/34123950/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": null,
    "supporting_quotes": [
      "We report the case of a 77-year-old man ... He died with neutropenia sepsis."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports a single case of a patient with a disease similar to CMML who received hydroxyurea and subsequently azacitidine.  No response rates or survival data are provided. The patient died from neutropenia sepsis.",
    "has_efficacy_data": false
  },
  {
    "pmid": "33792103",
    "citation": "{'name': 'Tremblay D', 'authtype': 'Author', 'clusterid': ''} et al. Contemporary Risk Stratification and Treatment of Chronic Myelomonocytic Leukemia.. The oncologist (2021 May)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33792103/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data on hydroxyurea treatment for CMML was found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "30169461",
    "citation": "{'name': 'Mora E', 'authtype': 'Author', 'clusterid': ''} et al. Current management of patients with chronic myelomonocytic leukemia.. Current opinion in oncology (2018 Nov)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/30169461/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "whereas those with myeloproliferative features generally receive hydroxyurea or HMAs but none of these drugs substantially modify the natural history of CMML."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 90,
    "efficacy_summary": "The review states that hydroxyurea, while used in CMML patients with myeloproliferative features, does not substantially modify the natural history of the disease.  No specific response rates or survival data for hydroxyurea in CMML are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "40411597",
    "citation": "{'name': 'Tran Quang V', 'authtype': 'Author', 'clusterid': ''} et al. Subclonal emergence of polycythemia vera, chronic myelomonocytic leukemia, and chronic myeloid leukemia.. Annals of hematology (2025 Jul)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40411597/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "The present longitudinal study reports a unique patient followed over almost three decades who sequentially developed polycythemia vera, chronic myelomonocytic leukemia, and chronic myeloid leukemia."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study reports on a single patient who developed CMML and received hydroxyurea treatment, but no specific efficacy data (response rates or survival) related to hydroxyurea in the context of CMML is provided.  The abstract focuses on the patient's treatment evolution and clonal dynamics, not quantitative efficacy assessments.",
    "has_efficacy_data": false
  },
  {
    "pmid": "28572287",
    "citation": "{'name': 'Solary E', 'authtype': 'Author', 'clusterid': ''} et al. How I treat chronic myelomonocytic leukemia.. Blood (2017 Jul 13)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/28572287/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The abstract does not provide any specific clinical efficacy data (response rates or survival data) for hydroxyurea treatment in CMML patients.  It only mentions hydroxyurea as a cytoreductive agent used in proliferative CMML and that current treatments barely modify disease evolution.",
    "has_efficacy_data": false
  },
  {
    "pmid": "26666606",
    "citation": "{'name': 'Imai H', 'authtype': 'Author', 'clusterid': ''} et al. Hydroxyurea-induced Pneumonitis in a Patient with Chronic Myelomonocytic Leukemia: An Autopsy Case.. Internal medicine (Tokyo, Japan) (2015)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/26666606/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "We describe the case of an 85-year-old man diagnosed with chronic myelomonocytic leukemia whose disease was treated with hydroxyurea for 3 months."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study only presents a single case study of a CMML patient treated with hydroxyurea.  No response rates or survival data are provided. The patient developed severe pneumonitis and died after 3 months of treatment.  Therefore, no meaningful efficacy data is available.",
    "has_efficacy_data": false
  },
  {
    "pmid": "36458426",
    "citation": "{'name': 'Bazinet A', 'authtype': 'Author', 'clusterid': ''} et al. A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.. Cancer (2023 Feb 15)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/36458426/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 33.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 54,
    "cmml_patients": 21,
    "supporting_quotes": [
      "The overall response rate was 33% in CMML (50% in HMA-naive CMML and 23% in HMA-failure CMML) and 48% in sAML (82% in HMA-naive sAML and 32% in HMA-failure sAML).",
      "The authors identified 21 patients with CMML (eight with HMA-naive CMML and 13 with HMA-failure CMML) and 33 patients with sAML (11 with HMA-naive sAML and 22 with HMA-failure sAML) treated with CLAD/LDAC/HMA-based regimens."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study focuses on Cladribine/Low-dose Cytarabine/Hypomethylating agent regimens, not Hydroxyurea.  An overall response rate of 33% was observed in the CMML group.  The study did not provide OS or PFS data for Hydroxyurea.",
    "has_efficacy_data": true
  },
  {
    "pmid": "24006407",
    "citation": "{'name': 'Onida F', 'authtype': 'Author', 'clusterid': ''} et al. Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups.. Haematologica (2013 Sep)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/24006407/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "Patients with myeloproliferative-type chronic myelomonocytic leukemia with a low number of blasts (<10%) should be treated with cytoreductive therapy. Hydroxyurea is the drug of choice to control cell proliferation and to reduce organomegaly."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 90,
    "efficacy_summary": "The provided text mentions Hydroxyurea as the drug of choice for cytoreductive therapy in myeloproliferative-type CMML with a low blast count (<10%), focusing on controlling cell proliferation and reducing organomegaly.  However, no quantitative efficacy data such as response rates or survival metrics are given.",
    "has_efficacy_data": false
  },
  {
    "pmid": "33126392",
    "citation": "{'name': 'Hu L', 'authtype': 'Author', 'clusterid': ''} et al. Chronic myelomonocytic leukemia (CMML)-0 with pleural effusion as first manifestation: A case report.. Medicine (2020 Oct 30)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33126392/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "Here we reported a rare case of CMML-0 with pleural effusion as the first manifestation in a 44-year-old woman.",
      "The patient was treated with azacitidine 75 mg/m d for 2 cycles, followed by daily oral intake of hydroxyurea (500 mg/d).",
      "Pleural effusion was resolved and chest pain was relieved."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "One CMML patient received hydroxyurea after azacitidine.  Pleural effusion resolved, suggesting a positive clinical response to the combined treatment, but no quantitative response rates or survival data are provided. ",
    "has_efficacy_data": false
  },
  {
    "pmid": "30367269",
    "citation": "{'name': 'Hunter AM', 'authtype': 'Author', 'clusterid': ''} et al. Current Management and Recent Advances in the Treatment of Chronic Myelomonocytic Leukemia.. Current treatment options in oncology (2018 Oct 27)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/30367269/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "Patients presenting with proliferative features can be treated with hydroxyurea to manage their symptoms and control leukocytosis, though HMAs can be incorporated as well, particularly in patients with higher risk disease."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 90,
    "efficacy_summary": "The abstract mentions hydroxyurea for managing symptoms and controlling leukocytosis in CMML patients with proliferative features.  No specific efficacy metrics (response rates or survival data) for hydroxyurea are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "35529292",
    "citation": "{'name': 'Nie Y', 'authtype': 'Author', 'clusterid': ''} et al. Atraumatic Splenic Rupture due to Chronic Myelomonocytic Leukemia Treated with Partial Splenic Artery Embolization.. Case reports in oncology (2022 Jan-Apr)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/35529292/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "We describe a patient with chronic myelomonocytic leukemia (CMML) ... On follow-up in clinic 2 months post-discharge, the patient was doing well on hydroxyurea, without need for further intervention at that time."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study is a single case report.  The patient with CMML showed a positive response to hydroxyurea treatment, with no need for further intervention after two months of follow-up. No quantitative efficacy data is available.",
    "has_efficacy_data": false
  },
  {
    "pmid": "34175902",
    "citation": "{'name': 'Renneville A', 'authtype': 'Author', 'clusterid': ''} et al. Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia.. Leukemia (2021 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/34175902/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 24.0,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "Median overall survival of this aggressive myeloid malignancy is only 2-3 years"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The abstract mentions a median overall survival of 2-3 years (24-36 months) for CMML patients.  No other efficacy data for hydroxyurea specifically is provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "39759649",
    "citation": "{'name': 'Arslan Davulcu E', 'authtype': 'Author', 'clusterid': ''} et al. A Case of Chronic Myelomonocytic Leukemia With Recurrent Skin Involvement.. Cureus (2024 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/39759649/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "This case study describes a 71-year-old male with high-risk CMML, developing pink-purple skin nodules, which regressed with azacitidine and hydroxyurea treatment."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 90,
    "efficacy_summary": "The case study reports regression of skin nodules in a single CMML patient treated with azacitidine and hydroxyurea.  No quantitative response rates or survival data are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "35992818",
    "citation": "{'name': 'Symeonidis A', 'authtype': 'Author', 'clusterid': ''} et al. Allogeneic Hematopoietic Stem Cell Transplantation for Mixed or Overlap Myelodysplastic/Myeloproliferative Disorders.. Frontiers in oncology (2022)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/35992818/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "Although patients with proliferative or dysplastic features may benefit from hydroxyurea and hypomethylating agent treatment, respectively, none of these treatments can establish long-term remission and prevent the inevitable transformation to acute leukemia."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 90,
    "efficacy_summary": "The abstract states that hydroxyurea may benefit some CMML patients, but it does not achieve long-term remission or prevent progression to acute leukemia.  No specific response rates or survival data for hydroxyurea in CMML are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "2593715",
    "citation": "{'name': 'Tefferi A', 'authtype': 'Author', 'clusterid': ''} et al. Chronic myelomonocytic leukemia: natural history and prognostic determinants.. Mayo Clinic proceedings (1989 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/2593715/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 36.0,
    "total_patients": 41,
    "cmml_patients": 41,
    "supporting_quotes": [
      "A retrospective clinical review of 41 patients with chronic myelomonocytic leukemia",
      "The median survival was 3 years."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports a median overall survival of 36 months (3 years). Hydroxyurea showed some efficacy in controlling leukocytosis and splenomegaly in some patients, but it did not affect the overall prognosis.",
    "has_efficacy_data": true
  },
  {
    "pmid": "34194799",
    "citation": "{'name': 'Nakako S', 'authtype': 'Author', 'clusterid': ''} et al. Successful management of therapy-related chronic myelomonocytic leukemia with cytarabine, aclarubicin, and azacitidine following tegafur/gimeracil/oteracil.. Clinical case reports (2021 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/34194799/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "A 55-year-old man was diagnosed with therapy-related chronic myelomonocytic leukemia (t-CMML) after exposure to tegafur/gimeracil/oteracil.",
      "Although he was refractory to hydroxyurea and low-dose cytarabine,"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study reports on a single patient refractory to hydroxyurea.  No response rates or survival data for hydroxyurea treatment are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "8839839",
    "citation": "{'name': 'Wattel E', 'authtype': 'Author', 'clusterid': ''} et al. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Fran\u00e7ais des My\u00e9lodysplasies and European CMML Group.. Blood (1996 Oct 1)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/8839839/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 60.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 20.0,
    "total_patients": 105,
    "cmml_patients": 105,
    "supporting_quotes": [
      "Response to treatment was seen in 60% of the pts in the HY group, versus 36%, respectively, in the VP16 group (P = .02).",
      "Median actuarial survival was 20 months in the HY arm, versus 9 months in the VP16 arm (P < 10(-4)).",
      "The study was closed on first interim analysis that showed a superiority of HY over VP16, after inclusion of 105 pts (HY arm: 53, VP16 arm: 52)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "Hydroxyurea demonstrated a 60% overall response rate and a median overall survival of 20 months in patients with advanced CMML.  This was significantly better than the VP16 arm.",
    "has_efficacy_data": true
  },
  {
    "pmid": "2052066",
    "citation": "{'name': 'Wolff-Kormann PG', 'authtype': 'Author', 'clusterid': ''} et al. Successful treatment with hydroxyurea of ocular involvement in chronic myelomonocytic leukemia.. The New England journal of medicine (1991 Jul 18)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/2052066/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "Extraction failed",
    "extraction_confidence": null,
    "efficacy_summary": "504 Deadline Exceeded",
    "has_efficacy_data": false
  },
  {
    "pmid": "6582939",
    "citation": "{'name': 'Solal-Celigny P', 'authtype': 'Author', 'clusterid': ''} et al. Chronic myelomonocytic leukemia according to FAB classification: analysis of 35 cases.. Blood (1984 Mar)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/6582939/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 15.83,
    "total_patients": 35,
    "cmml_patients": 35,
    "supporting_quotes": [
      "With conventional cytotoxic drugs (6-mercaptopurine, hydroxyurea), the prognosis of CMML appears poor (median survival 475 days)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports a poor prognosis for CMML patients treated with conventional cytotoxic drugs including hydroxyurea, with a median survival of 475 days (15.83 months).  No response rates are provided for hydroxyurea specifically.",
    "has_efficacy_data": true
  },
  {
    "pmid": "17404590",
    "citation": "{'name': 'LoSavio AD', 'authtype': 'Author', 'clusterid': ''} et al. Colonic infiltration with chronic myelomonocytic leukemia.. Nature clinical practice. Gastroenterology & hepatology (2007 Apr)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/17404590/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "A 75-year-old female presented with a 1 month history of non-bloody diarrhea, associated with abdominal cramping and urgency. Her medical history was notable for chronic myelomonocytic leukemia, diagnosed 6 years previously and managed expectantly by monitoring the patient's complete blood count.",
      "Management of underlying leukemia with systemic hydroxyurea and topical colonic 5-aminosalicylic acid therapy."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study describes a single case of CMML managed with hydroxyurea. No response rates or survival data are provided.  The patient's ultimate outcome was death due to complications.",
    "has_efficacy_data": false
  },
  {
    "pmid": "33513373",
    "citation": "{'name': 'Pleyer L', 'authtype': 'Author', 'clusterid': ''} et al. Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study.. The Lancet. Haematology (2021 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33513373/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 15.6,
    "total_patients": 949,
    "cmml_patients": 949,
    "supporting_quotes": [
      "Adjusted median overall survival for patients treated with hydroxyurea versus hypomethylating agents was 15.6 months (95% CI 13.1-17.3) versus 20.7 months (17.9-23.4); hazard ratio (HR) 1.39 (1.17-1.65; p=0.0002) and 14.0 months (9.8-17.2) versus 20.7 months (17.9-23.4; HR 1.55 [1.16-2.05]; p=0.0027) for those treated with intensive chemotherapy versus hypomethylating agents.",
      "412 (43%) of 949 patients received hypomethylating agents as first treatment, 391 (41%) hydroxyurea, and 83 (9%) intensive chemotherapy."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports a median overall survival of 15.6 months for CMML patients treated with hydroxyurea.  This was compared to 20.7 months for those receiving hypomethylating agents, indicating a shorter survival time with hydroxyurea.",
    "has_efficacy_data": true
  },
  {
    "pmid": "36282401",
    "citation": "{'name': 'Reiser J', 'authtype': 'Author', 'clusterid': ''} et al. Treatment options and survival in real life during the past three decades in patients with chronic myelomonocytic leukemia.. Wiener medizinische Wochenschrift (1946) (2023 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/36282401/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 168,
    "cmml_patients": 168,
    "supporting_quotes": [
      "In a retrospective observational study, we analyzed 168 CMML patients regarding treatment options and survival during the past three decades.",
      "The proportion of patients treated with hydroxyurea (HU), intensive chemotherapy, and azacitidine (AZA) was 65/19/0% before 2000, 51/25/32% from 2000-2010, and 36/12/53% after 2010, respectively.",
      "Median overall survival (OS) increased from 10 months before 2000 to 23 months thereafter (p = 0.021)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study shows a shift in treatment approaches over three decades, with hydroxyurea use decreasing from 65% before 2000 to 36% after 2010.  Median overall survival improved from 10 months to 23 months over this period, though this improvement isn't directly attributed to hydroxyurea as azacitidine use increased concurrently and showed a survival benefit. No response rates are reported for Hydroxyurea.",
    "has_efficacy_data": true
  },
  {
    "pmid": "34966690",
    "citation": "{'name': 'Liapis K', 'authtype': 'Author', 'clusterid': ''} et al. Approaching First-Line Treatment in Patients With Advanced CMML: Hypomethylating Agents or Cytotoxic Treatment?. Frontiers in oncology (2021)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/34966690/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The provided abstract does not contain any clinical efficacy data related to hydroxyurea treatment for CMML.",
    "has_efficacy_data": false
  },
  {
    "pmid": "21828134",
    "citation": "{'name': 'Braun T', 'authtype': 'Author', 'clusterid': ''} et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.. Blood (2011 Oct 6)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/21828134/",
    "drug": "hydroxyurea",
    "complete_response": 10.0,
    "partial_response": null,
    "marrow_complete_response": 21.0,
    "overall_response_rate": 38.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 39,
    "cmml_patients": 39,
    "supporting_quotes": [
      "Overall response rate was 38% with 4 complete responses (10%), 8 marrow responses (21%), and 3 stable diseases with hematologic improvement (8%).",
      "With a median follow-up of 23 months, overall survival was 48% at 2 years."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports an overall response rate of 38% to decitabine in 39 patients with advanced CMML.  Complete response rate was 10% and marrow response rate was 21%. Overall survival at 2 years was 48%.  Note that this data is for decitabine, not hydroxyurea.",
    "has_efficacy_data": true
  },
  {
    "pmid": "31699472",
    "citation": "{'name': 'Zhao Y', 'authtype': 'Author', 'clusterid': ''} et al. Sequential development of human herpes virus 8-positive diffuse large B-cell lymphoma and chronic myelomonocytic leukemia in a 59 year old female patient with hemoglobin SC disease.. Pathology, research and practice (2019 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/31699472/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "Herein, we report a unique case of sequential development of two separate hematolymphoid neoplasms, human herpes virus 8 (HHV8)-positive diffuse large B-cell lymphoma (DLBCL) and chronic myelomonocytic leukemia, in a 59 year-old African American female with hemoglobin SC disease."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The paper presents a single case study of a patient with CMML and does not provide any response rates or survival data related to hydroxyurea treatment.  The patient's CMML is mentioned in the context of potential causes, including hydroxyurea therapy, but no treatment outcomes are reported.",
    "has_efficacy_data": false
  },
  {
    "pmid": "11077120",
    "citation": "{'name': 'Strupp C', 'authtype': 'Author', 'clusterid': ''} et al. Pericardial effusion in chronic myelomonocytic leukemia (CMML): a case report and review of the literature.. Leukemia research (2000 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/11077120/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": 1,
    "supporting_quotes": [
      "Leukocytosis did not respond to hydroxyurea."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 90,
    "efficacy_summary": "The study reports a single case of CMML where hydroxyurea treatment showed no response to leukocytosis.  No other efficacy data (response rates or survival data) is available from the study.",
    "has_efficacy_data": false
  },
  {
    "pmid": "25982484",
    "citation": "{'name': 'Liang Y', 'authtype': 'Author', 'clusterid': ''} et al. Chronic myelomonocytic leukaemia associated with acquired haemophilia A: case report and literature review.. Haemophilia : the official journal of the World Federation of Hemophilia (2015 Jul)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/25982484/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No efficacy data on hydroxyurea treatment for CMML was found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "40613931",
    "citation": "{'name': 'Sastow D', 'authtype': 'Author', 'clusterid': ''} et al. Contemporary CMML Risk Stratification and Management.. Current hematologic malignancy reports (2025 Jul 4)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40613931/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "Established treatments, which include hypomethylating agents and hydroxyurea as well as the JAK1/2 inhibitor ruxolitinib, provide limited survival benefits in CMML, underscoring the urgent need for novel therapeutic development."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 60,
    "efficacy_summary": "The abstract mentions that hydroxyurea provides limited survival benefits but does not quantify this benefit with specific response rates or survival data.",
    "has_efficacy_data": false
  },
  {
    "pmid": "8528056",
    "citation": "{'name': 'Morschhauser F', 'authtype': 'Author', 'clusterid': ''} et al. Glomerular injury in chronic myelomonocytic leukemia.. Leukemia & lymphoma (1995 Aug)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/8528056/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 825,
    "cmml_patients": 4,
    "supporting_quotes": [
      "Among 825 cases of de novo myelodysplastic syndromes (MDS) diagnosed over a period of 13 years in our center, 4 had clinically significant glomerulopathy.",
      "All 4 fulfilled diagnostic criteria of chronic myelomonocytic leukemia (CMML), and could be classified in the low or intermediate risk groups according to two scoring systems.",
      "The 4 patients were treated with V16 or hydroxyurea and two had renal improvement."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The study mentions 4 CMML patients treated with hydroxyurea or V16, with two showing renal improvement.  No specific response rates or survival data are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "1494812",
    "citation": "{'name': 'Cavanna L', 'authtype': 'Author', 'clusterid': ''} et al. Acute myelocytic leukemia and chronic myelomonocytic leukemia simultaneously with resectable breast cancer: a report of two cases.. Tumori (1992 Oct 31)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/1494812/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 2,
    "cmml_patients": 1,
    "supporting_quotes": [
      "This report describes 2 patients who developed acute myelocytic leukemia (AML) type M2 and chronic myelomonocytic leukemia (CMML) of the FAB classification, respectively 2 months and 2 weeks after diagnosis of operable breast cancer.",
      "The patient with CMML had a normal karyotype, and she was treated with hydroxyurea and supportive therapy."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study reports on two patients, one with CMML treated with hydroxyurea and supportive therapy. No quantitative efficacy data (response rates or survival times) are provided for the CMML patient.",
    "has_efficacy_data": false
  },
  {
    "pmid": "34934616",
    "citation": "{'name': 'Gaur S', 'authtype': 'Author', 'clusterid': ''} et al. Post-operative hyperleukocytosis and leukostasis as the initial presentation of chronic myelomonocytic leukemia: A case report and review of literature.. Leukemia research reports (2021)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/34934616/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The provided abstract describes a single case report and a literature review of post-operative leukocytosis in CMML patients.  No quantitative efficacy data on hydroxyurea treatment for CMML is presented.",
    "has_efficacy_data": false
  },
  {
    "pmid": "14738156",
    "citation": "{'name': 'Robak T', 'authtype': 'Author', 'clusterid': ''} et al. Chronic myelomonocytic leukemia coexisting with B-cell chronic lymphocytic leukemia.. Leukemia & lymphoma (2003 Nov)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/14738156/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "Subsequently, she received hydroxyurea (1.5 g/day) without hematological improvement.",
      "The patient died in January 2003, three months after diagnosis because of progression of both leukemias and associated pneumonia."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "Hydroxyurea treatment showed no hematological improvement in the one CMML patient in the study. The patient died three months after diagnosis.",
    "has_efficacy_data": false
  },
  {
    "pmid": "34236344",
    "citation": "{'name': 'Schwede M', 'authtype': 'Author', 'clusterid': ''} et al. Diagnosis and management of neutrophilic myeloid neoplasms.. Clinical advances in hematology & oncology : H&O (2021 Jul)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/34236344/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data on hydroxyurea treatment for CMML patients was found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "27760943",
    "citation": "{'name': 'Sunami Y', 'authtype': 'Author', 'clusterid': ''} et al. [Chronic Myelomonocytic Leukemia with Myelofibrosis Resulting in Sudden Massive Pleural Effusion during Cytoreductive Therapy with Hydroxycarbamide].. Gan to kagaku ryoho. Cancer & chemotherapy (2016 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/27760943/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "Here, we report a case of CMML with bone marrow fibrosis, in which massive pleural effusion developed rapidly during cytoreductive therapy with hydroxycarbamide(HU).",
      "At the same time, the patient's leukocytosis was well controlled by the HU treatment."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 90,
    "efficacy_summary": "The study reports a single case of CMML treated with hydroxycarbamide.  Leukocytosis was controlled, but this is not a standard efficacy metric. No response rates or survival data are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "8683997",
    "citation": "{'name': 'Cambier N', 'authtype': 'Author', 'clusterid': ''} et al. All-trans retinoic acid in adult chronic myelomonocytic leukemia: results of a pilot study.. Leukemia (1996 Jul)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/8683997/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 10,
    "cmml_patients": 10,
    "supporting_quotes": [
      "we treated 10 cases of advanced adult CMML with ATRA (45 mg/m2/day)",
      "Four patients had a minor but significant response with reduction of transfusion requirement (two cases) or increase in platelet counts (two cases)"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The study focuses on ATRA, not Hydroxyurea, as the primary treatment. Hydroxyurea was added to ATRA in some patients to manage side effects.  While four patients had a minor response (reduction in transfusion needs or increased platelet counts), no specific response rates or survival data for Hydroxyurea treatment alone is provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "18651553",
    "citation": "{'name': 'Enriquez R', 'authtype': 'Author', 'clusterid': ''} et al. Severe renal complications in chronic myelomonocytic leukemia.. Journal of nephrology (2008 Jul-Aug)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/18651553/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "A 56-year-old man presented with peripheral monocytosis and massive nephrotic syndrome. He was diagnosed as having chronic myelomonocytic leukemia and membranous glomerulonephritis."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study presents a single case report of a CMML patient treated with hydroxyurea among other drugs. No quantitative efficacy data (response rates or survival) related specifically to hydroxyurea is provided. The patient received hydroxyurea but the outcome regarding nephrotic syndrome was not a complete resolution.",
    "has_efficacy_data": false
  },
  {
    "pmid": "6579877",
    "citation": "{'name': 'Petri M', 'authtype': 'Author', 'clusterid': ''} et al. Acquired factor XIII deficiency with chronic myelomonocytic leukemia.. Annals of internal medicine (1983 Nov)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/6579877/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No efficacy data on hydroxyurea treatment for CMML was found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "40415500",
    "citation": "{'name': 'Al-Nusair J', 'authtype': 'Author', 'clusterid': ''} et al. Nodal Mature Plasmacytoid Dendritic Cell Proliferation in a Patient With Chronic Myelomonocytic Leukemia: A Diagnostic Mimic of Blastic Plasmacytoid Dendritic Cell Neoplasm.. Journal of investigative medicine high impact case reports (2025 Jan-Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40415500/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "We report a 78-year-old male with CMML-1 and progressive cervical lymphadenopathy.",
      "The patient was initially treated with hydroxyurea, later transitioned to decitabine/cedazuridine (Inqovi) for disease progression. Follow-up marrow biopsy showed stable CMML-2 with persistent mutations, and the patient remains under close monitoring."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study reports on a single CMML patient treated with hydroxyurea.  No response rates or survival data are provided for hydroxyurea treatment. The patient showed stable disease progression after hydroxyurea,  requiring a switch to a different treatment.",
    "has_efficacy_data": false
  },
  {
    "pmid": "29102950",
    "citation": "{'name': 'Bargagli E', 'authtype': 'Author', 'clusterid': ''} et al. Fibrotic Lung Toxicity Induced by Hydroxycarbamide.. In vivo (Athens, Greece) (2017 Nov-Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/29102950/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "A patient treated for 4 months with hydroxycarbamide (hydroxyurea) for chronic myelomonocytic leukemia was admitted to hospital for recently developed severe dyspnea and acute respiratory failure."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study only describes a single case of a CMML patient treated with hydroxyurea. No efficacy data such as response rates or survival times were reported.  The focus of the paper is on a serious adverse event (lung toxicity).",
    "has_efficacy_data": false
  },
  {
    "pmid": "11976825",
    "citation": "{'name': 'Hur M', 'authtype': 'Author', 'clusterid': ''} et al. Lymphoid preponderance and the absence of basophilia and splenomegaly are frequent in m-bcr-positive chronic myelogenous leukemia.. Annals of hematology (2002 Apr)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/11976825/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 23,
    "cmml_patients": null,
    "supporting_quotes": [
      "A review of the 23 cases of m-bcr CML including this case showed the presence of monocytosis and the absence of basophilia and splenomegaly in 55.0%, 55.0%, and 70.0% of patients, respectively.",
      "Her clinical course was indolent and maintained the chronic phase of CML for nearly 3 years under hydroxyurea treatment."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The study mentions one patient with CML and monocytosis (resembling CMML) who had an indolent clinical course for three years under hydroxyurea treatment.  A review of 23 m-bcr CML cases shows some hematological features but no response rates or survival data related to hydroxyurea treatment are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "9088933",
    "citation": "{'name': 'Liozon E', 'authtype': 'Author', 'clusterid': ''} et al. Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature.. Hematology and cell therapy (1997 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/9088933/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 21,
    "total_patients": 58,
    "cmml_patients": 1,
    "supporting_quotes": [
      "From 1981 to 1995, we diagnosed, followed and treated at our institution fifty-eight cases of essential thrombocythemia (ET), using hydroxyurea (HU) as first-line therapy in these patients.",
      "Three patients who were continuously receiving HU had a leukemic transformation after a chronic phase of respectively 47, 81 and 90 months.",
      "the third patient developed a chronic myelomonocytic leukemia (CMML) and is alive at 21 months"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports on three patients with essential thrombocythemia who developed leukemic transformation while receiving hydroxyurea. One of these transformations was to CMML, with the patient surviving 21 months after diagnosis.  No response rates or PFS data is provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "24522248",
    "citation": "{'name': 'Pleyer L', 'authtype': 'Author', 'clusterid': ''} et al. Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival.. Leukemia research (2014 Apr)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/24522248/",
    "drug": "hydroxyurea",
    "complete_response": 22.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 70.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 6.2,
    "total_patients": 48,
    "cmml_patients": 48,
    "supporting_quotes": [
      "Overall response rates were high (70% according to IWG-criteria, including 22% complete responses).",
      "longer OS for azacitidine first-line vs. hydroxyurea first-line (p=0.072, median OS 27.7 vs. 6.2 months)"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study primarily focuses on azacitidine, showing a 70% overall response rate with a 22% complete response rate.  Hydroxyurea is mentioned in a comparison of overall survival with azacitidine, showing a significantly shorter median OS of 6.2 months for hydroxyurea first-line treatment compared to azacitidine.",
    "has_efficacy_data": true
  },
  {
    "pmid": "29383443",
    "citation": "{'name': 'Huemer F', 'authtype': 'Author', 'clusterid': ''} et al. Establishment and validation of a\u00a0novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia.. Wiener klinische Wochenschrift (2018 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/29383443/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 120,
    "cmml_patients": 120,
    "supporting_quotes": [
      "In multivariate analysis we identified elevated lactate dehydrogenase (>/=223 U/l), higher bone marrow blast percentage (>/=7.5%) and thrombocytopenia (<55 G/l) at initial diagnosis as the most relevant parameters for the time to first treatment.",
      "In the high-risk group (>/=2 risk factors) 85% of patients required treatment within 1 year, whereas this was the case in 48% in the intermediate-risk (1 risk factor) and in 0% in the low-risk group (0 risk factors).",
      "Using these three parameters we developed a risk score that efficiently estimates the time to treatment initiation with azacitidine or hydroxyurea (p < 0.001; log-rank)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The study focuses on predicting the time to first treatment (azacitidine or hydroxyurea) in CMML patients, not on treatment efficacy.  It identifies risk factors associated with earlier treatment initiation.  85% of high-risk patients required treatment within one year. No response rates or survival data are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "15101735",
    "citation": "{'name': 'Vural F', 'authtype': 'Author', 'clusterid': ''} et al. Gingival involvement in a patient with CD56+ chronic myelomonocytic leukemia.. Leukemia & lymphoma (2004 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/15101735/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "Here we report a case of CD56+ chronic myelomonocytic leukemia (CMML) who developed gingival involvement simultaneously when the leukocyte count elevated.",
      "Gingival hypertrophy regressed with the treatment of hydroxyurea.",
      "The patient is in complete hematological remission for one and a half years."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "Hydroxyurea treatment resulted in regression of gingival hypertrophy in one CMML patient.  The patient achieved complete hematological remission for 18 months after further treatment with an AML-like regimen.  However, this is a single case study and no response rates or survival data are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "34840744",
    "citation": "{'name': 'Abuzneid YS', 'authtype': 'Author', 'clusterid': ''} et al. Atypical CML with TET2 mutation, associated with NRAS and KRAS: A case report and literature review.. Annals of medicine and surgery (2012) (2021 Nov)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/34840744/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": null,
    "supporting_quotes": [
      "We present a case of a 55-year-old female ... The patient was started on Hydroxyurea for a duration of 9 months with an excellent initial response leading to normalization of her platelets and WBCs. However, in the last month she stopped responding to therapy and her state of health started declining once again."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The case report describes one patient with atypical CML who showed an initial excellent response to Hydroxyurea, with normalization of platelets and WBCs.  However, this response was not sustained, and the patient's health declined after 9 months.",
    "has_efficacy_data": false
  },
  {
    "pmid": "9580461",
    "citation": "{'name': 'Del Ca\u00f1izo MC', 'authtype': 'Author', 'clusterid': ''} et al. The value of cell cultures for the diagnosis of mixed myelodysplastic/myeloproliferative disorders.. Haematologica (1998 Jan)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/9580461/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 80,
    "cmml_patients": 8,
    "supporting_quotes": [
      "A total of 80 patients diagnosed as having MDS were included in the study.",
      "Among these 22 patients, eight were diagnosed as suffering from chronic myelomonocytic leukemia (CMML) according to the FAB criteria and were excluded from the present analysis.",
      "In one additional patient the platelet count increased up to 1000 x 10(9)/L and required treatment with hydroxyurea."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study provides the total number of patients and the number of CMML patients.  One patient with increased platelet count received hydroxyurea, but no efficacy data (response rates or survival) for hydroxyurea in CMML is reported.",
    "has_efficacy_data": false
  },
  {
    "pmid": "9585073",
    "citation": "{'name': 'Doll DC', 'authtype': 'Author', 'clusterid': ''} et al. Treatment with low-dose oral etoposide in patients with myelodysplastic syndromes.. Leukemia research (1998 Jan)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/9585073/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 70.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 43,
    "cmml_patients": 17,
    "supporting_quotes": [
      "Eighteen patients (42%) experienced hematological responses, including 12 of 17 (70%) patients with chronic myelomonocytic leukemia (CMML).",
      "Three of five CMML patients who failed treatment with hydroxyurea experienced major hematological responses with oral etoposide."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports a 70% overall response rate in CMML patients treated with oral etoposide, specifically noting that 3 out of 5 CMML patients who failed hydroxyurea treatment responded to etoposide.  No survival data is provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "10583263",
    "citation": "{'name': 'Ravandi F', 'authtype': 'Author', 'clusterid': ''} et al. Chronic myelogenous leukaemia with p185(BCR/ABL) expression: characteristics and clinical significance.. British journal of haematology (1999 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/10583263/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1384,
    "cmml_patients": null,
    "supporting_quotes": [
      "Results of Western blot analysis for 1384 patients referred with a diagnosis of CML to our institution from 1989 to 1997 were reviewed.",
      "The clinical course and therapy of the patients varied, with one patient receiving hydroxyurea only, three patients receiving hydroxyurea followed by interferon-alpha based regimens and bone marrow transplantation."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The study focuses on CML, not CMML.  While it mentions hydroxyurea treatment in some CML patients, no response rates or survival data are provided for this treatment.  The total number of patients in the CML study is stated.",
    "has_efficacy_data": false
  },
  {
    "pmid": "30150344",
    "citation": "{'name': 'Vig S', 'authtype': 'Author', 'clusterid': ''} et al. Opioid toxicity with underlying tumour lysis syndrome in a patient with CMML: a diagnostic and therapeutic challenge.. BMJ case reports (2018 Aug 27)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/30150344/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "We report a unique case of chronic myelomonocytic leukaemia presenting with opioid toxicity overlapping with tumour lysis syndrome.",
      "The patient was on hydroxyurea-based chemotherapy for the primary disease."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study presents a single case report of a CMML patient treated with hydroxyurea.  No response rates or survival data are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "16104083",
    "citation": "{'name': 'Beli\u0107 A', 'authtype': 'Author', 'clusterid': ''} et al. [Our experiences in the treatment of myelodysplastic syndromes].. Medicinski pregled (1992)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/16104083/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 42,
    "cmml_patients": 2,
    "supporting_quotes": [
      "From 1987 an abrupt increase of the number of patients presented with MDS has been registered. We present our experiences in the treatment of 42 patients.",
      "CMML. in only 5% of the cases.",
      "The treatment improved hematologic results but the complete remission lacked."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The study mentions that hydroxyurea treatment for CMML patients (n=2) improved hematologic results, but complete remission was not achieved.  No specific response rates or survival data are provided for the CMML patients treated with hydroxyurea.",
    "has_efficacy_data": false
  },
  {
    "pmid": "15359914",
    "citation": "{'name': 'Watanabe N', 'authtype': 'Author', 'clusterid': ''} et al. [Pleural involvement in the course of chronic myelomonocytic leukemia and the development of multiple colonic perforation due to leukemic infiltration in the acute leukemia phase].. [Rinsho ketsueki] The Japanese journal of clinical hematology (2004 Jul)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/15359914/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "A 68-year-old man with chronic myelomonocytic leukemia (CMML) was initially treated with hydroxyurea with subsequent stable disease."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study describes a single case of CMML treated with hydroxyurea, resulting in stable disease. No response rates or survival data are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "8922495",
    "citation": "{'name': 'Muroi K', 'authtype': 'Author', 'clusterid': ''} et al. Therapy-related chronic myelomonocytic leukaemia with bone marrow eosinophilia associated with der(11)t(1;11)(q21;q14).. Acta haematologica (1996)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/8922495/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "A 19-year-old male with chronic myelomonocytic leukaemia (CMML) with bone marrow eosinophilia terminating in myeloblastic transformation is described.",
      "He was treated with hydroxyurea to control the leucocyte count, but myeloblastic transformation developed."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study describes a single case of CMML treated with hydroxyurea.  The treatment resulted in leucocyte count control, but ultimately failed to prevent myeloblastic transformation.  No quantitative efficacy data is provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "11908732",
    "citation": "{'name': 'Shen Y', 'authtype': 'Author', 'clusterid': ''} et al. Pentasomy 8q resulting from duplication of isochromosome 8q in chronic myelomonocytic leukemia.. Leukemia & lymphoma (2002 Jan)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/11908732/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 5,
    "total_patients": 3,
    "cmml_patients": 3,
    "supporting_quotes": [
      "Hydroxyurea and 6-mercaptopurine therapy did not induce a complete remission and five months later he died of exacerbation of his disease.",
      "On reviewing another two cases with pentasomy 8q in the literature, we feel that pentasomy 8q, when present as a sole anomaly, may play a specific role in leukemogenesis and in determining the clinical characteristics such as monocytic involvement and poor prognosis."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports on three patients with CMML and pentasomy 8q.  One patient treated with hydroxyurea and 6-mercaptopurine showed no response and died after five months. No response rates or PFS data is provided.  The study focuses on cytogenetics and prognosis, rather than treatment efficacy.",
    "has_efficacy_data": true
  },
  {
    "pmid": "16447718",
    "citation": "{'name': 'Yamazaki E', 'authtype': 'Author', 'clusterid': ''} et al. [Chronic myelomonocytic leukemia with pleural effusion as the first clinical sign].. [Rinsho ketsueki] The Japanese journal of clinical hematology (2005 Mar)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/16447718/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "A 61-year-old male was referred to our hospital because of leukocytosis with blasts and pleural effusion with chest pain.",
      "After the leukocytosis was brought under control with hydroxycarbamide, the patient's pleural effusion disappeared."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The study reports a single case of CMML where hydroxycarbamide (hydroxyurea) controlled leukocytosis and resolved pleural effusion.  No quantitative response rates or survival data are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "40365824",
    "citation": "{'name': 'Chen H', 'authtype': 'Author', 'clusterid': ''} et al. KDM6A Deficiency Induces Myeloid Bias and Promotes CMML-Like Disease Through JAK/STAT3 Activation by Repressing SOCS3.. Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2025 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40365824/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The provided abstract does not contain any clinical efficacy data related to Hydroxyurea treatment for CMML. The study focuses on the role of KDM6A and the JAK/STAT pathway in CMML pathogenesis and suggests potential therapeutic avenues, but it does not report on the efficacy of any specific treatment, including Hydroxyurea.",
    "has_efficacy_data": false
  },
  {
    "pmid": "39766092",
    "citation": "{'name': 'Wei Q', 'authtype': 'Author', 'clusterid': ''} et al. Detection of KMT2A Partial Tandem Duplication by Optical Genome Mapping in Myeloid Neoplasms: Associated Cytogenetics, Gene Mutations, Treatment Responses, and Patient Outcomes.. Cancers (2024 Dec 16)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/39766092/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1277,
    "cmml_patients": 5,
    "supporting_quotes": [
      "In this study, we evaluated KMT2A PTD in 1277 patients with hematological malignancies using optical genome mapping (OGM).",
      "KMT2A PTD was detected in ... 5 patients with chronic myelomonocytic leukemia (CMML) (7.1%).",
      "All but one patient with MDS and CMML were refractory to therapy."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study mentions that all but one CMML patient were refractory to therapy, indicating poor treatment response.  No specific data on response rates or survival for CMML patients treated with Hydroxyurea is provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "28119224",
    "citation": "{'name': 'Gur HD', 'authtype': 'Author', 'clusterid': ''} et al. Clinical significance of isolated del(7p) in myeloid neoplasms.. Leukemia research (2017 Apr)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/28119224/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 10,
    "cmml_patients": 1,
    "supporting_quotes": [
      "Here we report 10 patients with isolated del(7p), 4 had acute myeloid leukemia (AML), 2 myelodysplastic syndromes (MDS), 1 chronic myelomonocytic leukemia (CMML), 1 primary myelofibrosis (PMF), and 2 AML in remission.",
      "Detection of del(7p) in patients with MDS, CMML, or PMF appeared to predict poorer prognosis as all 4 patients experienced disease progression or transformation to AML after 5-24 months."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 90,
    "efficacy_summary": "The study reports on 10 patients with del(7p), including one with CMML.  No response rates or survival data specific to Hydroxyurea treatment are provided.  The CMML patient experienced disease progression after 5-24 months.  The study focuses on the prognostic significance of del(7p), not treatment efficacy.",
    "has_efficacy_data": false
  },
  {
    "pmid": "30054307",
    "citation": "{'name': 'Loghavi S', 'authtype': 'Author', 'clusterid': ''} et al. Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories.. Blood advances (2018 Aug 14)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/30054307/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 629,
    "cmml_patients": 629,
    "supporting_quotes": [
      "a large single-institution CMML patient cohort (n = 629) was used to assess the prognostic impact of the newly proposed categories",
      "MP-CMML patients had significantly shorter overall survival (OS; P < .0001; hazard ratio: 0.53, 95% confidence interval: 0.42-0.65) and median duration to acute myeloid leukemia (AML) transformation (P < .0001; 15.2 vs 22.0 months) compared with MDS-CMML patients"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study analyzed overall survival (OS) and time to AML transformation in different CMML subgroups based on the 2017 WHO classification.  No response rates were reported.  MP-CMML patients showed significantly shorter OS and time to AML transformation compared to MDS-CMML patients.  The study did not focus on Hydroxyurea treatment efficacy.",
    "has_efficacy_data": false
  },
  {
    "pmid": "25965571",
    "citation": "{'name': 'Colla S', 'authtype': 'Author', 'clusterid': ''} et al. Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome.. Cancer cell (2015 May 11)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/25965571/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data on hydroxyurea treatment for CMML patients was found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "28115276",
    "citation": "{'name': 'Liu HD', 'authtype': 'Author', 'clusterid': ''} et al. Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation (2017 May)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/28115276/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 209,
    "cmml_patients": 209,
    "supporting_quotes": [
      "From 2001 to 2012, 209 adult subjects who received HCT for CMML were reported to the Center for International Blood and Marrow Transplant Research.",
      "Respective 1-year, 3-year, and 5-year survival rates for low/intermediate-1 risk subjects were 61% (95% confidence interval [CI], 52% to 72%), 48% (95% CI, 37% to 59%), and 44% (95% CI, 33% to 55%), and for intermediate-2/high risk subjects were 38% (95% CI, 28% to 49%), 32% (95% CI, 21% to 42%), and 19% (95% CI, 8% to 29%).",
      "Median follow-up was 51 months (range, 3 to 122)"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports 1-year, 3-year, and 5-year survival rates for CMML patients undergoing HCT, stratified by CPSS risk score.  No response rates are provided.  The median follow-up time was 51 months.",
    "has_efficacy_data": true
  },
  {
    "pmid": "28621841",
    "citation": "{'name': 'Zeidan AM', 'authtype': 'Author', 'clusterid': ''} et al. Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study.. Cancer (2017 Oct 1)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/28621841/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 13,
    "total_patients": 1378,
    "cmml_patients": 1378,
    "supporting_quotes": [
      "Among 1378 older adults diagnosed with CMML, the median OS was 13 months",
      "In the primary matched analysis, with 225 HMA users diagnosed in 2007-2011 and 395 patients diagnosed in 2001-2003, the median OS times were 17 and 11 months, respectively"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study focuses on hypomethylating agents (HMAs), not hydroxyurea.  Overall survival (OS) median was 13 months for all 1378 CMML patients.  A subgroup analysis of HMA users showed median OS of 17 months, while a comparison group had 11 months.  No response rates were reported.",
    "has_efficacy_data": true
  },
  {
    "pmid": "29288910",
    "citation": "{'name': 'Hu Z', 'authtype': 'Author', 'clusterid': ''} et al. 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.. Leukemia research (2018 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/29288910/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 13.4,
    "total_patients": 12,
    "cmml_patients": 10,
    "supporting_quotes": [
      "The median follow-up was 11.5 months (range, 1.5-24 months) and at time of last follow-up, 11 (92%) died with a median survival of 13.4 months (range, 1.5-24 months).",
      "The study group included 12 cases of MDS/MPN with 3q26.2 rearrangements detected by conventional karyotyping.",
      "Ten cases were classified as chronic myelomonocytic leukemia (CMML) and 2 were MDS/MPN, unclassifiable."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports a median overall survival of 13.4 months for patients with MDS/MPN and 3q26.2/EVI1 rearrangements.  No response rates to specific treatments, including hydroxyurea, are provided. ",
    "has_efficacy_data": true
  },
  {
    "pmid": "38411250",
    "citation": "{'name': 'Mosquera Orgueira A', 'authtype': 'Author', 'clusterid': ''} et al. Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification.. British journal of haematology (2024 Apr)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/38411250/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1418,
    "cmml_patients": 1418,
    "supporting_quotes": [
      "In the Spanish cohort, the AIPSS-MDS accurately predicted overall survival (OS) and leukaemia-free survival (LFS), outperforming the Revised-IPSS score.",
      "Similarly, in the Taiwanese cohort, the AIPSS-MDS demonstrated accurate predictions for OS and LFS, showing superiority over the IPSS score and performing better than the CPSS and molecular CPSS scores in differentiating patient outcomes.",
      "This study aimed to validate the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes (AIPSS-MDS) in CMML and to assess its performance compared with traditional scores using data from a Spanish registry (n = 1343) and a Taiwanese hospital (n = 75)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The study focuses on validating a prognostic scoring system (AIPSS-MDS) for CMML, assessing its performance in predicting overall survival (OS) and leukemia-free survival (LFS).  No response rates or specific treatment efficacy data for hydroxyurea are provided. The total number of patients included in the study is 1418.",
    "has_efficacy_data": false
  },
  {
    "pmid": "10648421",
    "citation": "{'name': 'Hu ZB', 'authtype': 'Author', 'clusterid': ''} et al. Regulation of drug sensitivity by ribosomal protein S3a.. Blood (2000 Feb 1)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/10648421/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 32,
    "cmml_patients": null,
    "supporting_quotes": [
      "In 32 cryopreserved blast populations, S3a levels were significantly correlated with both bcl-2 and with cell growth in culture."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The study investigated the correlation between ribosomal protein S3a levels and response to treatment in AML and CMML patients.  While 32 cryopreserved blast samples were analyzed, no specific response rates or survival data related to hydroxyurea treatment for CMML were reported.",
    "has_efficacy_data": false
  },
  {
    "pmid": "23251462",
    "citation": "{'name': 'Lamothe B', 'authtype': 'Author', 'clusterid': ''} et al. Deletion of TAK1 in the myeloid lineage results in the spontaneous development of myelomonocytic leukemia in mice.. PloS one (2012)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/23251462/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 30,
    "cmml_patients": null,
    "supporting_quotes": [
      "Consequently, we found TAK1 deletion in 13 of 30 AML patients (43%), thus providing direct genetic evidence of TAK1's role in leukemogenesis."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 90,
    "efficacy_summary": "The study provides the total number of AML patients (30) but does not contain any information regarding hydroxyurea treatment or clinical efficacy metrics such as response rates or survival data for CMML patients.",
    "has_efficacy_data": false
  },
  {
    "pmid": "2280603",
    "citation": "{'name': 'Fenaux P', 'authtype': 'Author', 'clusterid': ''} et al. de novo myelodysplastic syndromes in adults aged 50 or less. A report on 37 cases.. Leukemia research (1990)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/2280603/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 21,
    "total_patients": 37,
    "cmml_patients": 9,
    "supporting_quotes": [
      "Twenty-one patients received intensive chemotherapy (at diagnosis or during the evolution) but only 8 (38%) achieved complete remission (CR), and median CR duration was 10 months.",
      "Median actuarial survival of the 37 patients was 21 months.",
      "At diagnosis, there were 9 CMML but no RARS."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports a median overall survival of 21 months for 37 patients with de novo myelodysplastic syndromes, including 9 with CMML.  No specific efficacy data for hydroxyurea is provided.  The study mentions that 8 out of 21 patients receiving intensive chemotherapy achieved complete remission.",
    "has_efficacy_data": true
  },
  {
    "pmid": "25332630",
    "citation": "{'name': 'Ramzan M', 'authtype': 'Author', 'clusterid': ''} et al. Juvenile myelomonocytic leukemia in India: cure remains a distant dream!. Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion (2014 Sep)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/25332630/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 8,
    "cmml_patients": null,
    "supporting_quotes": [
      "We report a series of eight children."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study reports on eight children with Juvenile Myelomonocytic Leukemia (JMML), not Chronic Myelomonocytic Leukemia (CMML).  No efficacy data related to Hydroxyurea treatment for CMML is provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "3113160",
    "citation": "{'name': 'von Eyben FE', 'authtype': 'Author', 'clusterid': ''} et al. High-voltage irradiation and hydroxyurea for pulmonary leukostasis in acute myelomonocytic leukemia.. Acta haematologica (1987)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/3113160/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 0,
    "supporting_quotes": [
      "A 29-year-old man with acute myelomonocytic leukemia had an initial leukocyte count of 192 X 10(9) cells/l and 84% blasts."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The abstract describes a single case of acute myelomonocytic leukemia (AML), not CMML, treated with hydroxyurea.  Pulmonary leukostasis developed, which responded to radiation. No response rates or survival data for hydroxyurea treatment in CMML are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "29050457",
    "citation": "{'name': 'Bertolini F', 'authtype': 'Author', 'clusterid': ''} et al. Skin nodules in onset of acute myeloid leukemia, a myelomonocytic variant case.. Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia (2017 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/29050457/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No efficacy data on hydroxyurea treatment for CMML was found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "10072111",
    "citation": "{'name': 'Saitoh T', 'authtype': 'Author', 'clusterid': ''} et al. Myelodysplastic syndromes with nephrotic syndrome.. American journal of hematology (1999 Mar)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/10072111/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 125,
    "cmml_patients": 11,
    "supporting_quotes": [
      "We enrolled 125 patients with MDS who were admitted between January 1979 and May 1996 in this study.",
      "Three of the total 11 patients with CMMOL were diagnosed as having nephrotic syndrome.",
      "One CMMOL patient was treated with VP-16 and hydroxyurea. As the white blood cell count in this patient decreased, the 24-hr urine protein excretion and the serum tumor necrosis factor alpha level decreased."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study mentions one CMML patient treated with hydroxyurea and VP-16, showing a decrease in white blood cell count, 24-hr urine protein excretion, and serum TNF-alpha levels.  However, no quantitative efficacy metrics (response rates or survival data) are provided for hydroxyurea treatment in CMML patients.",
    "has_efficacy_data": false
  }
]